Dx&Vx is showing strong performance. The news that it has completed the patent application for its self-developed low-molecular GLP-1 receptor agonist oral obesity treatment (GLP-1RA) appears to be influencing its stock price.
As of 9:45 AM on the 26th, Dx&Vx is trading at 4,280 KRW, up 6.2% compared to the previous trading day.
The core of the patent application candidate substance lies in its structural originality compared to existing developers. It overcomes the inconvenience of injection administration and high production costs, which are drawbacks of existing peptide-based GLP-1RA treatments. It is designed for oral administration. By minimizing degradation in the gastrointestinal tract and increasing bioavailability, it can maximize therapeutic effects.
Starting with the patent application, Dx&Vx plans to promptly proceed with additional research and development such as animal testing and to fully prepare for entering clinical trials. Through partnerships with multiple global pharmaceutical companies, it will also lay the groundwork for global clinical trials and market entry.
CEO Kwon Kyu-chan said, "The patent application, which was advanced ahead of the original plan, is an example that demonstrates the company's outstanding research and development capabilities and rapid development speed," adding, "It reflects the company's strong commitment to new drug development." He continued, "We will also deliver results quickly in clinical trials and commercialization stages," emphasizing, "We will establish a leading position in the global obesity treatment market, which is expected to grow to a market size of 100 trillion KRW by 2030."
Dx&Vx is expanding its new drug pipeline targeting various indications. It views the patent application for this oral obesity treatment (GLP-1RA) candidate substance as an important turning point in new drug development.
Earlier, on the 23rd, Dx&Vx announced that its microbiome research institute discovered an anti-obesity probiotic strain and completed its patent application. DX2034 is an anti-obesity strain that can reduce body fat and be effective in early-stage obesity.
Dx&Vx is expanding its obesity and metabolic disease-related pipeline through additional development of anti-obesity strains. The GLP (glucagon-like peptide)-1 oral obesity treatment is preparing multiple early patent applications for substances and plans to pursue early commercialization through additional research such as animal experiments. If the anti-obesity strains are recognized for functionality through human trials, a mass production system will also be established in the future.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
